The aforementioned variables, including MRM, larger tumor size, lymph node involvement, PgR positivity, and hormone therapy (except for tamoxifen), acted as independent prognostic factors for DFS events in the 10-year follow-up. This evidence concerns the gene PGR and neoplasm.